AR
XENE icon

Advisory Research’s Xenon Pharmaceuticals XENE Stock Holding History

Advisory Research’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-38,326
Closed -$1.31M – 483
2023
Q3 		$1.31M Sell
38,326
-6,096
-14% -$228K 0.18% 157
2023
Q2 		$1.71M Buy
44,422
+17,582
+66% +$699K 0.22% 126
2023
Q1 		$961K Sell
26,840
-5,891
-18% -$218K 0.16% 159
2022
Q4 		$1.29M Sell
32,731
-3,707
-10% -$135K 0.12% 126
2022
Q3 		$1.32M Buy
36,438
+1,438
+4% +$51.7K 0.13% 126
2022
Q2 		$1.06M Buy
+35,000
New +$1.06M 0.1% 152

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisory Research's XENE Position: Q4 2023 in Review

Advisory Research sold out of Xenon Pharmaceuticals (XENE) in Q4 2023, closing a stake of 38,326 shares — an estimated $1.31M sold.

Advisory Research first reported a position in XENE in Q2 2022 and held it in 6 quarters. The position peaked at $1.71M in Q2 2023. 204 funds tracked by Wall St. Rank hold XENE as of Q4 2023.

  • Advisory Research reported no remaining Xenon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Advisory Research sold 38,326 Xenon Pharmaceuticals shares in Q4 2023, an estimated $1.31M.
  • Advisory Research first reported a position in Xenon Pharmaceuticals in Q2 2022 and held it in 6 quarters.
  • Advisory Research's Xenon Pharmaceuticals position peaked at $1.71M in Q2 2023.
  • 204 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2023.

Based on Advisory Research's 13F filing for Q4 2023, filed 13 Feb 2024.